Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7838055 | 0.83 | CYP3A4 (0.44) | KDM4EALDH1A1GLAHPGDSMN1; SMN2 | |
| SCHEMBL3227644 | 0.82 | GRIN2D (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1320586 | 0.71 | KDM4E (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11675400 | 0.71 | KDM4E (0.36) | KDM4EALDH1A1HPGD | |
| SCHEMBL7784289 | 0.70 | GRIN2D (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1827309 | 0.67 | CYP3A4 (0.44) | KDM4EALDH1A1GLAHPGDSMN1; SMN2 | |
| SCHEMBL157744 | 0.64 | CYP3A4 (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL586536 | 0.63 | KDM4E (0.33) | KDM4EALDH1A1HPGD | |
| SCHEMBL9999337 | 0.61 | — | — | |
| Hydrochloric Acid SCHEMBL2948518 | 0.61 | MAPT (0.38) | KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-06-12 | — | — | US | disclosed |
| US-7282575-B2 | Functional peptide nucleic acid monomer and process for producing the same | CREDIA JAPAN CO., LTD. (JP) | 2007-10-16 | — | — | US | disclosed |
| US-20040101839-A1 | Novel functional peptide nucleic acid monomer and process for producing the same | CREDIA JAPAN CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1357112-A1 | NOVEL FUNCTIONAL PEPTIDE NUCLEIC ACID MONOMER AND PROCESS FOR PRODUCING THE SAME | Applied Biosystems Japan Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040101839-A1 | Novel functional peptide nucleic acid monomer and process for producing the same | NSUN3, NSUN2, RNGTT | GRIN2D 3157/4885GRIN3B 2439/4885GRIN1 3721/4885 |
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | NSUN3, RNGTT, NSUN2 | GRIN2D 3405/4885GRIN3B 2421/4885GRIN1 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.